Global Postpartum Depression Market - 2023-2030

Global Postpartum Depression Market - 2023-2030

Global Postpartum Depression Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.

The global postpartum depression market witnessing significant growth and transformations in recent years, with various factors influencing its dynamics such as increasing prevalence, rising clinical trials, and others. Government investments are continuously rising for better patient counseling and treatment for the patients, this will continue to drive and boost the global market. The global postpartum depression market is placing increasing emphasis to reduce its impact through novel treatment options.

Moreover, patients with postpartum depression usually experience emotional highs and lows, frequent crying, fatigue, guilt, anxiety, and may have trouble caring for their baby. Postpartum depression can be commonly treated with medication and counseling. The treatment is based on the type and state of the disease. Psychotherapy, antidepressants, anti-anxiety medications, and others are used in the treatment of postpartum depression. Psychotherapy is considered a first-line treatment.

Similarly, North America dominates the postpartum depression market, capturing the largest market share owing to the region’s favorable reimbursement policies, advanced healthcare infrastructure, and presence of major players.

Owing to the factors such as increasing prevalence, growing awareness and better treatment, rising clinical trials, increasing demand for novel therapeutics, increasing demand for psychotherapy, and advancements in treatment options are expected to drive the global postpartum depression market over the forecast period.

Dynamics

Increasing Research Activities and Clinical Trials are Expected to Drive the Growth of the Market

There are continuously increasing research activities and clinical trials, which are expected to drive market share over the forecast period. The increasing research activities and clinical trials in the field of postpartum depression helps in the development of advanced treatment options for the better treatment by considering the safety and efficacy of the treatment and with affordable costs. The research activities in the field of postpartum depression mainly focus on early drug absorption, which helps to reduce the symptoms early.

For instance, on September 26, 2022, Brii Biosciences Limited, a multi-national company developing innovative therapies, announced top-line results from a Phase 1 study evaluating its long-acting, single-injection therapy, BRII-296, in development for the treatment of postpartum depression (PPD). These data show that a single treatment via intramuscular (IM) injection of 600 mg of BRII-296 achieved dose linearity, early drug absorption, and gradual and extended-release profiles without the need for dose titration or tapering, providing confidence that this dose has the potential to achieve clinical efficacy in the treatment of PPD.

Moreover, the ongoing research activities on postpartum depression enhance the treatment opportunities with better patient outcomes, and the development of innovative treatment approaches has led to the discovery of potentially novel treatment options such as light therapies for enhanced treatment. These advancements increase the way for the introduction of novel drugs and therapies by reducing the symptoms.

For instance, on October 13, 2022, the University of Michigan announced that they started recruiting for clinical trials on a wearable morning light treatment for postpartum depression. This study will test a consumer health light therapy device (Re-Timer) for women with postpartum depression to better understand how it affects mood and the body clock (also called the circadian clock). It is estimated that the study will end on May 13, 2025.

Increasing Demand for Innovative Therapeutics is Expected to Drive the Growth of the Postpartum Depression Market

There increasing demand for innovative therapeutics, which is expected to drive the market over the forecast period. The existing therapies such as psychotherapy and various antidepressants and anti-anxiety medicines show good results. But, still, there is a continuously increasing demand for innovative therapeutics like novel antidepressant drugs with enhanced results by identifying the severity of the disease and reducing the symptoms in a very short period.

For instance, on August 04, 2023, Biogen Inc. and Sage Therapeutics, Inc. announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAE (zuranolone) 50 mg for adults with postpartum depression (PPD). ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with PPD. ZURZUVAE is expected to launch and be commercially available in the fourth quarter of 2023 shortly following scheduling as a controlled substance by the U.S. Drug Enforcement Administration, which is anticipated to occur within 90 days.

Moreover, some patients with postpartum depression may get confused about their condition and situation, so early detection may helps to reduce the severity of the condition. The innovative tests and AI technologies are helps to identify the disease at home in the early stages. This early detection of the condition helps to treat the condition in the early stages with novel therapeutics which shows better results.

For instance, on April 03, 2023, UVA Health and Dionysus Digital Health, a digital health start-up aims to launch an at-home blood test and AI-driven app this fall that could predict the risk of postpartum depression as early as in the third trimester. Still in its early stages, the company eventually intends to file for US FDA clearance of the test.

Lack of Knowledge and Awareness is Expected to Hamper the Market's Growth

The lack of knowledge and awareness about postpartum depression and its associated medications is expected to hamper the growth of the market. The awareness of postpartum depression may helps in the early detection and seeks to better treatment, but this lack of awareness may leads to the severity of the condition. Limited awareness can result in less funding for research into postpartum depression, potentially slowing down the development of innovative diagnostic methods and treatment options.

When postpartum depression is not promptly recognized and treated, it can worsen over time, leading to more severe symptoms and longer recovery periods. This delayed treatment can have long-term implications for both the mother and the child. Many cases of postpartum depression go undiagnosed or untreated due to a lack of awareness about the condition. Women and healthcare providers may not recognize the symptoms, leading to missed opportunities for intervention and treatment.

Segment Analysis

The global postpartum depression market is segmented based on type, treatment, end-user and region.

The Psychotherapy Segment Accounted for Approximately 45.3% of the Postpartum Depression Market Share

The psychotherapy segment is expected to hold the largest market share over the forecast period. Psychotherapy is also known as talk therapy or mental health counseling. The therapy helps to talk through the patient's concerns with a psychiatrist, psychologist, or other mental health professional. Through this therapy, patients can find better ways to cope with their feelings, solve problems, set realistic goals, and respond to situations in a positive way. Sometimes family or relationship therapy also helps. Psychotherapy for postpartum depression includes cognitive-behavioral therapy (CBT) and interpersonal psychotherapy.

Moreover, psychotherapy is a non-invasive treatment option, making it preferable for many women who may be hesitant to take medication during pregnancy or while breastfeeding. It also carries fewer side effects compared to some medications. This therapy can be tailored to the individual's specific needs and circumstances. Therapists work with clients to address their unique experiences and challenges associated with postpartum depression. Many clinical trials and research activities are still going for innovations in psychotherapy or novel psychotherapy.

For instance, on October 29, 2022, the Weill Medical College of Cornell University announced that they are started the clinical trials for a novel social reward psychotherapy for postpartum depression. This study tests a novel psychotherapy, Engage & Connect, tailored to reduce postpartum depression. The study includes 9 weeks of psychotherapy, delivered remotely. It will examine changes in social isolation, processing of social rewards, and depression severity over 9 weeks of treatment. It is estimated that the study will end on July 29, 2027.

Geographical Penetration

North America Accounted for Approximately 39.7% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Well-Established Healthcare Infrastructure

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and well-established healthcare infrastructure. North America especially the United States and Canada is home to many pharmaceutical, research institutes, and medical device companies. The region’s strong presence of major players will be forefront in performing clinical trials and research activities which leads to the launch of innovative therapeutics.

For instance, on June 08, 2022, Anthem Inc., the largest for-profit managed healthcare company and a provider of health insurance in the United States, announced that it will offer a digital solution to mothers in order to support maternal mental healthcare needs. The payer partnered with a vendor, Happify Health, to offer a tool that mothers can use to support their recovery from postpartum depression.

Furthermore, North America is also known for its advanced and well-established healthcare infrastructure including hospitals, specialty clinics, psychiatric centers, and others which operates and treats patients with advanced therapies and novel drugs which results in better patient outcomes. The improved insurance coverage offers the better treatment for many patients at affordable costs, leading to market dominance in the region.

Competitive Landscape
The major global players in the postpartum depression market include Biogen Pharmaceuticals, Sage Therapeutics, Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Plc, Mallinckrodt Pharmaceuticals, Dr. Reddy's Laboratories, Sandoz, Amneal Pharmaceuticals Pvt. Ltd., and Servier Laboratories Ltd. among others.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical industries worldwide, including the global postpartum depression market. During the pandemic, many clinical trials and research activities on postpartum depression have been temporarily disrupted and regulatory approvals have been temporarily postponed due to the redirected focus on the COVID-19 pandemic.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions due to the severity of COVID-19, impacting regular pregnancy and postpartum check-ups, appointments, and consultations worldwide. Many hospitals are focused on the COVID-19 cases, this reduced the focus on the postpartum depression related treatments.

Moreover, the COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials of postpartum depression therapeutics such as anti-depressants and others. Movement restrictions and border closures delayed shipments and caused drug transportation delays. Additionally, some countries faced shortages of drugs for treatment due to disruptions in their supply chain networks.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global postpartum depression market owing to the absence of key market players in this region. The impact of the import and export of raw materials is expected to have little influence over the global postpartum depression market growth over the forecast period.

By Type
• Postpartum Blues (baby blues)
• Postpartum Anxiety
• Postpartum Obsessive-Compulsive Disorder (OCD)
• Postpartum Panic Disorder
• Postpartum Post-Traumatic Stress Disorder (PTSD)
• Postpartum Psychosis

By Treatment
• Anti-Anxiety or Antidepressant Medicines
• Psychotherapy
Cognitive-Behavioral Therapy (CBT)
Interpersonal Psychotherapy
• Electroconvulsive Therapy (ECT)
• Others

By End-User
• Hospitals
• Specialty Clinics
• Psychiatric Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• On December 15 2022, Pranaiya and Arthur Magoffin Foundation (PAM Foundation) is proud to announce a collaboration with the University of Oxford focused on postpartum depression (PPD) and other perinatal mental health illnesses.
• On June 30 2022, Curio Digital Therapeutics and Axia Women’s Health, one of the nation’s largest independent women’s health groups, are pleased to announce a collaboration agreement to help women at risk for postpartum depression and those diagnosed with postpartum depression. Through the launch of Curio’s MamaLift program, patients can access a web-based program that offers personalized self-help tools and trackers to help manage symptoms of anxiety and depression.

DataM Intelligence Opinion:

According to the DataM Intelligence, the postpartum depression market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increasing prevalence and novel therapeutic innovations for better treatment of depression. Many innovative treatment options are going to develop in the coming years by reducing the adverse effects with affordable costs and for effective treatment. Moreover, many clinical trials and research activities are still going, which is expected to growth of the global postpartum depression market in the upcoming years.

Why Purchase the Report?
• To visualize the global postpartum depression market segmentation based on type, treatment, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of postpartum depression market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global postpartum depression market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies